For NFE2L2 in lung squamous cell carcinoma, while the APSiC rank for the LK2 cells with the gain-of-function p.E79K mutation (82) was < 0.001, the APSiC rank for EBC1 with the rarer p.D77V mutation was 0.83, suggesting that p.D77V may not critical to the survival of the EBC1 cells. Here, NFE2L2 is linked to squamous cell lung carcinoma.